Preexposure Prophylaxis for HIV Prevention in the United States: An Overview and Update

被引:2
作者
Dhir, Amit Mickey [1 ,2 ]
机构
[1] Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21205 USA
[2] Chase Brexton Hlth Care, Baltimore, MD 21201 USA
关键词
Ending the HIV Epidemic; HIV; preexposure prophylaxis; PrEP; prevention; public health; sexual health assessment; CONDOM EFFECTIVENESS; MEN; EMTRICITABINE;
D O I
10.1097/01.NAJ.0000997216.21988.19
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
There were 36,136 new HIV diagnoses in the United States and dependent areas in 2021, despite a 12% reduction in estimated HIV incidence from 2017 to 2021. The burden of HIV remains disproportionately high among certain populations, including gay and bisexual men, Black/African American individuals, and Hispanic/Latino individuals, and racial and ethnic health care disparities persist. The Ending the HIV Epidemic initiative aims to significantly reduce new infections, with a focus on HIV prevention, particularly the use of preexposure prophylaxis (PrEP). However, challenges remain in achieving equitable PrEP distribution. As frontline health care providers, nurses play a pivotal role in this battle against HIV. This article provides an update on PrEP screening recommendations, the types of PrEP available, dosing, adverse effects, and the role of nurses in patient support and monitoring. The author provides an update on preexposure prophylaxis (PrEP) screening recommendations, the types of PrEP available, dosing, adverse effects, and the role of nurses in patient support and monitoring.
引用
收藏
页码:54 / 62
页数:9
相关论文
共 23 条
[1]   Primary HIV-1 infection in users of pre-exposure prophylaxis [J].
Ambrosioni, Juan ;
Petit, Elisa ;
Liegeon, Geoffroy ;
Laguno, Montserrat ;
Miro, Jose M. .
LANCET HIV, 2021, 8 (03) :e166-e174
[2]  
[Anonymous], 2022, Pre-Exposure Prophylaxis (PrEP)
[3]  
[Anonymous], 2021, COPD death rates in the United States
[4]  
[Anonymous], 2023, History of Ebola Outbreaks
[5]  
[Anonymous], 2023, . Estimated HIV incidence and prevalence in the United States, V28
[6]  
[Anonymous], 2023, Recommendations for the use of nirsevimab against respiratory syncytial virus for the 2023-2024 season. Working Group on the use of nirsevimab against respiratory syncytial virus infection from the Vaccination Program and Registry Panel
[7]  
[Anonymous], 2023, HHS Ready, Set, PrEP
[8]   Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis [J].
Blair, Hannah A. .
DRUGS, 2022, 82 (14) :1489-1498
[9]  
Centers for Disease Control and Prevention, 2023, HIV incidence
[10]   Preexposure Prophylaxis for the Prevention of HIV: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force [J].
Chou, Roger ;
Spencer, Hunter ;
Bougatsos, Christina ;
Blazina, Ian ;
Ahmed, Azrah ;
Selph, Shelley .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (08) :746-763